VIR Vir Biotechnology, Inc.
Vir Biotechnology, Inc. (VIR) Insider Activity
What the officers, directors and large holders did with their own shares. Only open-market purchases and sales count toward the totals — grants, option exercises and shares withheld for tax are compensation mechanics, not decisions, and they're listed separately below.
How much of that selling was preplanned? 100% planned / 0% discretionary
Largest single sale: $664.4K.
Where they traded
No open-market insider purchase on record.
Recent open-market activity
| Date | Insider | Role | Action | Shares | Price | Value | Held after |
|---|---|---|---|---|---|---|---|
| Napolitano Janet | Director | Sell 10b5-1 | 3,200 | $9.45 | $30.2K | 21,216 −13.1% of holding | |
| Sabatini Brent | SVP, Chief Accounting Officer | Sell 10b5-1 | 379 | $9.45 | $3.6K | 61,902 −0.6% of holding | |
| SATO VICKI L | Director | Sell 10b5-1 | 22,000 | $10.05 | $221.0K | 1,078,391 −2% of holding | |
| De Backer Marianne | President and CEO | Sell 10b5-1 | 72,559 | $9.16 | $664.4K | 948,145 −7.1% of holding | |
| SATO VICKI L | Director | Sell 10b5-1 | 22,000 | $9.07 | $199.6K | 1,100,391 −2% of holding | |
| Sabatini Brent | SVP, Chief Accounting Officer | Sell 10b5-1 | 7,711 | $9.12 | $70.3K | 61,902 −11.1% of holding |
Form 4s are due within two business days of a transaction, so this is close to real time — unlike the quarterly 13F data on the Institutional tab. A single large sale often reflects a prearranged 10b5-1 plan rather than a fresh view, so read a pattern of sales rather than any one of them.